Ruthenium polypyridine complex as well as preparation method and anti-tumor application thereof
The preparation of ruthenium polypyridine complex by introducing large conjugated dip ligands and specific synthetic methods has solved the problem that the wavelength is not in the ideal range in photodynamic therapy, and efficient killing of tumor cells is achieved, which has significantly improved the effect of photodynamic therapy.
Patent Information
- Application Number
- CN202410973722.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-19
AI Technical Summary
The existing ruthenium (II) complexes have photoactivation wavelengths not within the ideal range of 600 to 900 nm in photodynamic therapy, resulting in poor tissue permeability. Traditional chemotherapeutic drugs such as cisplatin have toxic side effects and drug resistance problems, making it difficult to effectively treat tumors. .
By introducing large conjugated dip ligands, the absorption wavelength of the ruthenium polypyridine complex is adjusted, extended to 750 nm, and the [Ru(dip)2(dpb)](Cl2) complex is prepared by specific synthetic methods to improve its in-light Effects of dynamic anti-tumor in.
The ruthenium polypyridine complex was achieved to produce 102 under light conditions, which significantly improved the toxicity to human lung cancer cell A549 and human cervical cancer cell Hela, and had good photodynamic therapeutic effects. The cytotoxicity index PI* was 17.6 and 9.3, respectively. Significantly better than cisplatin.
Smart Images

Figure CN118909003A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of metal complexes, and in particular to a ruthenium polypyridine complex and a preparation method and anti-tumor application thereof. Background Art
[0002] Cisplatin is one of the most effective chemotherapy drugs used clinically so far, but its application is limited by its toxic side effects and the easy development of drug resistance. Transition metal complexes, especially ruthenium complexes, have become the most promising alternatives to platinum drugs due to their low toxicity, easy absorption and metabolism, and selectivity for certain tumor cells.
[0003] Photodynamic therapy (PDT) activates photosensitizers with light of a specific wavelength to produce cytotoxic singlet oxygen, thereby killing tumor cells. This therapy avoids the systemic toxicity of traditional chemotherapy drugs and has good therapeutic selectivity. Ruthenium (II) complexes show good application prospects in PDT due to their unique photophysical properties, including long-lived excited states and adjustable emission wavelengths.
[0004] The ideal phototherapy window is between 600 and 900 nm. How to move the photoactivation wavelength of Ru(Ⅱ)-based phototherapy preparations to the phototherapy window to achieve deeper tissue penetration is a huge challenge currently faced. The photophysical properties of Ru(Ⅱ) polypyridine complexes (including absorption, emission, and excited state lifetime) depend on the ligands bound to the Ru center, so their photophysical properties can be adjusted by selecting appropriate auxiliary ligands. By introducing dip ligands with a large conjugated system, the absorption wavelength of ruthenium complexes can be red-shifted to approach the phototherapy window. At the same time, dip ligands are highly hydrophobic and can be effectively taken up by cells, so the complexes of the Ru-dip system usually also show efficient cellular uptake. Summary of the invention
[0005] The first object of the present invention is to provide a ruthenium polypyridine complex, the absorption wavelength of which can be extended to 750nm.
[0006] The second object of the present invention is to provide a method for preparing a ruthenium polypyridine complex.
[0007] The third object of the present invention is to provide a ruthenium polypyridine complex for use in photodynamic anti-tumor therapy.
[0008] The present invention is achieved through the following technical solutions:
[0009] The structural formula of a ruthenium polypyridine complex is shown in Formula 1:
[0010]
[0011] Abbreviated as [Ru(dip)2(dpb)](Cl2).
[0012] The preparation method of the ruthenium polypyridine complex comprises the following steps:
[0013] S1. Dissolve RuCl3·xH2O, dip and LiCl in 15mL N-N-dimethylformamide (DMF) solution, heat and reflux for 24h, cool to room temperature, add appropriate amount of acetone, and place in a -20℃ refrigerator for 4h to precipitate a large amount of purple-brown precipitate, filter and obtain [Ru(dip)2(Cl)2];
[0014] S2. Dissolve 2,2'-pyridone and 2,3-diaminonaphthalene in anhydrous ethanol, reflux for 3 h, cool, precipitate a large amount of yellow-brown needle-shaped solids, filter, and obtain bidentate ligand dpb;
[0015] S3. [Ru(dip)2(Cl)2] and dpb were weighed in a three-necked flask according to the stoichiometric ratio (1:1), and a mixed solution of ethanol and water (volume ratio of 1:1) was added, heated to reflux for 3 h, cooled to room temperature, filtered, and the filtrate was dried to obtain a reddish-brown solid crude product;
[0016] S4. Add a small amount of dichloromethane to dissolve the solid, add petroleum ether dropwise and shake, solid precipitates, filter and wash the precipitate with water and ether, and finally vacuum dry to obtain the ruthenium polypyridine complex.
[0017] Preferably, steps S1, S3 and S4 are all performed under light-proof conditions.
[0018] Preferably, steps S1 and S3 are performed under the protection of an inert gas, nitrogen.
[0019] The synthetic route of the present invention is as follows:
[0020]
[0021] The present invention has the following technical effects:
[0022] The complex of the present invention can produce 1 O2. CCK8 experiments showed that compared with the chemotherapy drug cisplatin, the complex has stronger toxicity to human lung cancer cells A549 and human cervical cancer cells Hela, and the phototoxicity index (PI*) for the two cells is 17.6 and 9.3, respectively, indicating that it has a good photodynamic therapy effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Attached Figure 1 This is a UV-visible absorption spectrum of the ruthenium polypyridine complex obtained in Example 1 of the present invention in acetonitrile.
[0024] Attached Figure 2 This is an absorption quenching diagram of the ruthenium polypyridine complex obtained in Example 1 of the present invention for 1,3-diphenylisobenzofuran (DPBF) at 410 nm under irradiation with emission light (λ=522 nm).
[0025] Attached Figure 3 This is a diagram showing the generation of reactive oxygen species (ROS) in cells by the ruthenium polypyridine complex obtained in Example 1 of the present invention.
[0026] Attached Figure 4 The figures are comparison graphs of the cell survival rates of the ruthenium polypyridine complex obtained in Example 1 of the present invention and the reference compound cisplatin under different conditions. (a) and (b) are comparison graphs of the survival rates of the ruthenium polypyridine complex on A549 cells under light (λ=470nm) and dark conditions, respectively; (c) and (d) are comparison graphs of the survival rates of the ruthenium polypyridine complex on Hela cells under light and dark conditions, respectively.
[0027] Attached Figure 5 This is a graph showing the live and dead cell staining results of the ruthenium polypyridine complex obtained in Example 1 of the present invention on human lung cancer cells (A549) under dark and light (λ=470nm) conditions.
[0028] Attached Figure 6 This is a graph showing the cell apoptosis rate result of the ruthenium polypyridine complex obtained in Example 1 of the present invention stained with Annexin V-FITC / PI. DETAILED DESCRIPTION
[0029] The technical solution of the present invention is further described below in conjunction with the accompanying drawings and specific examples. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in each embodiment of the present invention described below can be combined with each other as long as they do not conflict with each other.
[0030] Unless otherwise specified, the experimental methods used in the following experimental examples are all conventional methods; the materials and reagents used are reagents and materials that can be purchased from commercial channels unless otherwise specified.
[0031] Embodiment 1, the synthesis method of the complex, the steps are as follows:
[0032] S1. Weigh 196.5mg RuCl3·xH2O, 511.9mg dip ligand and 223.2mg LiCl and dissolve them in 15mL DMF solution. Heat and reflux for 24h under N2 protection at 150℃. Cool to room temperature, add excess acetone, and place in a -20℃ refrigerator for 4h. A large amount of purple-brown crystals will precipitate. Filter and wash with water, and dry the solid to obtain [Ru(dip)2(Cl)2]. The above reaction equation is as follows:
[0033]
[0034] S2. Dissolve 848.2 mg of 2,2'-pyridone and 633.4 mg of 2,3-diaminonaphthalene in 30 mL of anhydrous ethanol and heat under reflux for 3 h at 75°C. Cool and a large amount of yellow-brown needle-shaped solids precipitate, which are filtered and dried to obtain the bidentate ligand dpb. The above reaction equation is as follows:
[0035]
[0036] S3. Accurately weigh 166.4 mg [Ru(dip)2(Cl)2] and 132.8 mg dpb and dissolve them in a mixed solution of ethanol and water (volume ratio is 1:1), and heat under reflux for 3 h at 90°C under N2 protection. After cooling, filter and spin dry to obtain a reddish brown crude product.
[0037] S4. The solid crude product is dissolved with a small amount of dichloromethane, and a small amount of petroleum ether is added dropwise to precipitate the precipitate, which is filtered and washed with water and ether. The ruthenium polypyridine complex is obtained after the solid is dried. After drying, the yield is calculated by weighing.
[0038] The structural formula of the ruthenium polypyridine complex is as follows:
[0039]
[0040] It is abbreviated as [Ru(dip)2(dpb)](Cl2), and the yield is 32.2%.
[0041] H NMR spectrum: 1H NMR(600MHz,in[D6]DMSO)δ8.89(d,J=6.0Hz,1H),8.87(s,1H),8.81(dd,J=1.2,4.8Hz,1H),8.73(d,J=5.4Hz,1H) ,8.54(d,J=6.0Hz,1H),8.41(d,J=9.0Hz,1H),8.35(dd,J=9.6,7.8Hz,2H),8.31(s,1H),8.27(m,1H),8.20(t,J=8. 4Hz,2H),8.13(d,J=5.4Hz,1H),8.05(d,J=4.2Hz,1H),7.98(dd,J=9.6,6.0Hz,2H),7.91(dd,J=6.0,1.2Hz,2H),7. 76(m,4H),7.67(m,10H),7.60–7.54(m,9H),7.49(dd,J=3.0,1.2Hz,3H),7.46(d,J=8.4Hz,1H),7.41–7.37(m,1H).
[0042] Example 2, UV-visible absorption spectrum measurement of the ruthenium polypyridine complex obtained in Example 1
[0043] The UV-visible absorption spectrum of the ruthenium polypyridine complex was tested, and the results showed that its absorption wavelength can be extended to 750nm, which is in the phototherapy window range. Figure 1 .
[0044] Example 3, Determination of Singlet Oxygen Quantum Yield of Ruthenium Polypyridine Complex Obtained in Example 1
[0045] Determination of the complex in acetonitrile solution by DPBF 1 O2 quantum yield. DPBF is a highly efficient singlet oxygen scavenger that can be used with 1 O2 reacts in the acetonitrile solution, causing the absorbance of DPBF at 410nm to decrease. Select [Ru(bpy)3] 2+ As a standard substance, its concentration in acetonitrile solution is 1 The quantum yield of O2 is 0.57. 2+ Adjust the absorption at 522nm to the same value, add DPBF, mix well, irradiate with 522nm excitation light, and monitor the change of absorbance value of DPBF at λ=410nm. Figure 2 As shown, the ruthenium polypyridine complex was measured 1 The O2 quantum yield is 0.54.
[0046] Example 4, ROS experiment of the ruthenium polypyridine complex obtained in Example 1 in cells
[0047] 2'7'-Dichlorofluorescein diacetate (DCFH-DA) was used as a fluorescent probe to detect the production of ROS in cells by the ruthenium polypyridine complex. A549 cells were seeded in a six-well plate and divided into a light group and a dark group, and cultured in a constant temperature incubator (37°C, 5% CO2) for 24 hours. Ruthenium polypyridine complex (2μM) was added, incubated for 4 hours, the drug solution was discarded and washed twice with PBS, 15μM DCFH-DA probe was added, cultured in a constant temperature incubator for 30 minutes, washed 3 times with PBS, and the light group was illuminated with an LED dual-channel controller (λ=470nm) for 20 minutes, and the production of ROS was observed with an inverted fluorescence microscope. The results are shown in Figure 3 As shown, after being exposed to light, the complex showed obvious green fluorescence, indicating that it produced ROS in the cells.
[0048] Example 5, Cytotoxicity Test of Ruthenium Polypyridine Complex Obtained in Example 1
[0049] The phototoxicity and dark toxicity of the complex to A549 cells and Hela cells were investigated using the CCK8 experiment, and the chemotherapy drug cisplatin was used as a reference. The specific steps are as follows: Take well-growing A549 cells and Hela cells, digest and centrifuge them, and then plant them in a 96-well plate at a density of 5000 to 10000 per well, incubate them in a constant temperature incubator (37°C, 5% CO2) for 24 hours, discard the old culture medium, add different concentrations of ruthenium polypyridine complex [Ru(dip)2(dpb)](Cl2) and cisplatin, and continue to culture for 4 hours. The light group is illuminated with an LED dual-channel controller (λ=470nm) for 15 minutes, and then continue to culture for 20 hours. The dark group is not illuminated, and the other conditions are the same as the light group. After adding the CCK8 reagent and culturing for 1 hour, the OD value at 450nm is detected with an enzyme marker to obtain the cell survival rate under different conditions (see Figure 4 ), and calculate IC 50 The results are shown in Table 1. Compared with the chemotherapy drug cisplatin, the ruthenium polypyridine complex is more toxic, and the complex exhibits light-enhanced cytotoxicity to both cells. Under light conditions, the IC value of the ruthenium polypyridine complex on A549 cells 50 The value is 0.7 μmol / L, and the PI* value is 17.6; for Hela cells, the IC 50 The value is 1.1μmol / L, and the PI* value is 9.3. This result shows that the complex has a good photodynamic therapy effect. In addition, the ruthenium polypyridine complex has high lipophilicity and is easily taken up by cells, which may be the reason for its strong cytotoxicity.
[0050] Table 1 IC values of the complexes with cisplatin on A549 and Hela cells under light and dark conditions 50 value
[0051]
[0052] PI*=Dark IC 50 / Light IC 50
[0053] Example 6, Live and Dead Cell Staining Experiment of Ruthenium Polypyridine Complex Obtained in Example 1
[0054] In this experiment, human lung cancer cells A549 were selected as model tumor cells. The well-growing A549 cells were digested and centrifuged, and seeded in a six-well plate at a density of 20,000 per well. They were divided into two groups, light and dark, and cultured in a constant temperature incubator (37°C, 5% CO2) for 24 hours. The old culture medium was discarded, and the ruthenium polypyridine complex (5μM) was added to co-incubate with the cells for 4 hours. Then the light group was illuminated for 15 minutes using an LED dual-channel controller (λ=470nm) and continued to be cultured for 20 hours. Except for no illumination, the other conditions of the dark group were the same as those of the light group. After discarding the drug solution and washing with PBS, the diluted Meilun Biological Cell Viability Detection Reagent (the concentration of Calcein AM is 1μM, the concentration of PI is 4μM, live cells appear green and dead cells appear red) was added, and incubated at 37°C in the dark for 30 minutes. Finally, the live and dead cell staining results were detected using an inverted fluorescence microscope. The results are shown in Figure 5 As shown, after drug treatment, the number of dead cells in the light-irradiated group was significantly higher than that in the dark, indicating that the cytotoxicity of the ruthenium polypyridine complex after light irradiation was greater than that produced in the dark.
[0055] Example 7, apoptosis experiment of ruthenium polypyridine complex obtained in Example 1
[0056] The cell death mechanisms include necrosis and apoptosis, which are usually stained with Annexin V-FITC / PI (propidium iodide) and detected using a flow cytometer. First, take the well-grown A549 cells, digest and centrifuge them to make a cell suspension, and inoculate them in a six-well plate at a density of 50,000 per well. They are divided into a light group and a dark group and cultured in a constant temperature incubator (37°C, 5% CO2) for 24 hours. Then add 1mL (1.2μM) of the ruthenium polypyridine complex, and continue to culture for 4 hours. The light group is illuminated for 15 minutes using an LED dual-channel controller (λ=470nm), and then cultured for another 20 hours. The dark group is not illuminated, and the other conditions are the same as the light group. After staining with the AnnexinV-FITC / PI cell apoptosis detection kit, the cells are detected using a flow cytometer. The results are as follows Figure 6 As shown, after drug treatment, the sum of the upper right and lower right quadrants of the light group was higher than that of the dark group and other control groups, indicating that the ruthenium complex mainly causes cell death through the apoptosis pathway and that the drug toxicity is greater under light conditions.
[0057] The embodiments described in the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the scope of the present invention. Based on the above description, there may be other different forms of changes, and it is impossible to list all the changes here. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solution of the present invention by ordinary technicians in this field should all fall within the scope of protection determined by the claims of the present invention.
Claims
1. A ruthenium polypyridine complex, characterized in that: The molecular formula is [(Ru(dip)2(dpb)](Cl2); wherein dip is 4,7-diphenyl-1,10-phenanthroline, and dpb is a bidentate ligand synthesized from 2,2'-pyridone and 2,3-diaminonaphthalene; it has a structure as described in Formula 1 below:
2. The method for preparing a ruthenium polypyridine complex according to claim 1, characterized in that: The method comprises the following preparation steps: S1. Dissolve RuCl3·xH2O, dip and LiCl in 15mL NN-dimethylformamide (DMF) solution, heat and reflux for 24h, cool to room temperature, add appropriate amount of acetone, place in a -20℃ refrigerator for 4h, a large amount of purple-brown precipitate is precipitated, filter to obtain [Ru(dip)2(Cl)2]; S2. Dissolve 2,2'-pyridone and 2,3-diaminonaphthalene in anhydrous ethanol, reflux for 3 h, cool, precipitate a large amount of yellow-brown needle-shaped solids, filter, and obtain bidentate ligand dpb; S3. [Ru(dip)2(Cl)2] and dpb were weighed in a three-necked flask according to the stoichiometric ratio (1:1), and a mixed solution of ethanol and water (volume ratio of 1:1) was added, heated to reflux for 3 h, cooled to room temperature, filtered, and the filtrate was dried to obtain a reddish-brown solid crude product; S4. Add a small amount of dichloromethane to dissolve the solid, add petroleum ether dropwise and shake, solid precipitates, filter and wash the precipitate with water and ether, and finally vacuum dry to obtain the ruthenium polypyridine complex.
3. The method for preparing a ruthenium polypyridine complex according to claim 2, characterized in that: The steps S1, S3 and S4 are all performed under light-proof conditions.
4. The method for preparing a ruthenium polypyridine complex according to claim 2, characterized in that: The steps S1 and S3 are carried out under the protection of inert gas nitrogen.
5. Use of the ruthenium polypyridine complex according to claim 1 in the preparation of photodynamic anti-tumor drugs.
Citation Information
Patent Citations
Ruthenium arene complex with multiple activities as well as preparation method and application of ruthenium arene complex
CN114891041A
Preparation and anti-tumor application of carrier-free multifunctional nanoparticles based on ruthenium complex
CN115554401A
